Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434890 | 1.00 | SMN1; SMN2 (0.38) | SMN1; SMN2TAAR1AKR1B1ALDH1A1KDM4E | |
| SCHEMBL4799665 | 0.85 | IDO1 (0.37) | TAAR1ALDH1A1KDM4EKMT2AIDO1 | |
| SCHEMBL4796836 | 0.85 | SMN1; SMN2 (0.48) | SMN1; SMN2TAAR1AKR1B1ALDH1A1KDM4E | |
| SCHEMBL28905460 | 0.83 | SMN1; SMN2 (0.40) | SMN1; SMN2TAAR1AKR1B1ALDH1A1KDM4E | |
| SCHEMBL14954170 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2TAAR1ALDH1A1KDM4EKMT2A | |
| SCHEMBL12016024 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2TAAR1AKR1B1KDM4EPOLB | |
| SCHEMBL21027998 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2TAAR1AKR1B1ALDH1A1KDM4E | |
| SCHEMBL11462339 | 0.77 | TAAR1 (0.41) | SMN1; SMN2TAAR1AKR1B1ALDH1A1KDM4E | |
| SCHEMBL6734384 | 0.76 | ALDH1A1 (0.47) | SMN1; SMN2TAAR1AKR1B1ALDH1A1IDO1 | |
| SCHEMBL3220315 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2TAAR1AKR1B1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4608802-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XV | BASF SE (DE) | 2025-09-03 | — | — | EP | disclosed |
| US-12065399-B2 | Arylsulfonamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-08-20 | — | — | US | disclosed |
| WO-2024088792-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XV | BASF SE (DE) | 2024-05-02 | — | — | WO | disclosed |
| EP-4361126-A1 | USE OF STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI CONTAINING AN AMINO ACID SUBSTITUTION F129L IN THE MITOCHONDRIAL CYTOCHROME B PROTEIN CONFERRING RESISTANCE TO QO INHIBITORS XV | BASF SE (DE) | 2024-05-01 | — | — | EP | disclosed |
| CN-117088884-A | Imidazopyridazine derivatives as GABAA receptor modulators, pharmaceutical compositions and uses | 上海赛默罗德生物科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-B1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | HOFFMANN LA ROCHE (CH) | 2023-09-27 | — | — | EP | disclosed |
| EP-4013495-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2022-06-22 | — | — | EP | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2022-06-02 | — | — | US | disclosed |
| CN-114174266-A | Arylsulfonamide derivatives as MGLUR4 negative allosteric modulators | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | disclosed |
| WO-2021256881-A1 | ORGANIC LIGHT-EMITTING COMPOUND AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | 솔루스첨단소재 주식회사 | 2021-12-23 | — | — | WO | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028512-A1 | ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169599-A1 | ARYLSULFONAMIDE DERIVATIVES | ARSA, SULT1E1, STS | SMN1; SMN2 1681/4885TAAR1 1025/4885AKR1B1 393/4885 |
| US-12065399-B2 | Arylsulfonamide derivatives | ARSA, SULT1E1, STS | SMN1; SMN2 1681/4885TAAR1 1025/4885AKR1B1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.